Palvella Therapeutics (PVLA) Debt to Equity (2013 - 2025)
Palvella Therapeutics (PVLA) reported Debt to Equity of $0.08 for Q4 2025, up 148.39% year-over-year from $0.03 in Q4 2024, and up 36.99% quarter-over-quarter from $0.06 in Q3 2025.
Palvella Therapeutics (PVLA) Debt to Equity (2013 - 2025) Analysis & Trends
Palvella Therapeutics (PVLA) has 4 years of Debt to Equity data on file, last reported at $0.08 in Q4 2025.
- Debt to Equity for Q4 2025 came in at $0.08, up 148.39% year-over-year; the trailing twelve-month figure through Dec 2025 was $0.08 (up 148.39% YoY), and the FY2025 annual result was $0.08, up 148.39% from the prior year.
- Debt to Equity advanced to $0.08 in Q4 2025 per PVLA's latest filing, from $0.06 in the prior quarter.
- Over five years, Debt to Equity peaked at $0.08 in Q4 2025 and troughed at $0.03 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.08 |
| Sep 30, 2025 | 0.06 |
| Jun 30, 2025 | 0.04 |
| Mar 31, 2025 | 0.04 |
| Dec 31, 2024 | 0.03 |
| Dec 31, 2014 | 0.07 |
| Sep 30, 2014 | -4.37 |
| Jun 30, 2014 | 0.09 |
| Mar 31, 2014 | -0.52 |
| Dec 31, 2013 | 2.82 |
| Jun 30, 2013 | 0.10 |